Neutropenia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 74 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Neutropenia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Neutropenia - Pipeline Review, H2 2014', provides an overview of the Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neutropenia Overview 8
Therapeutics Development 9
Pipeline Products for Neutropenia - Overview 9
Pipeline Products for Neutropenia - Comparative Analysis 10
Neutropenia - Therapeutics under Development by Companies 11
Neutropenia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Neutropenia - Products under Development by Companies 16
Neutropenia - Companies Involved in Therapeutics Development 17
Hospira, Inc. 17
Gamida Cell Ltd. 18
Ligand Pharmaceuticals, Inc. 19
Cleveland BioLabs, Inc. 20
CSL Limited 21
ProMetic Life Sciences Inc. 22
Green Cross Corporation 23
Genexine, Inc. 24
USV Limited 25
Pfenex Inc. 26
Mycenax Biotech Inc. 27
NAL Pharmaceuticals Ltd. 28
Inbiopro Solutions Pvt. Ltd. 29
Neutropenia - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
pegfilgrastim - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GC-003 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
romyelocel-L - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GXG-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
filgrastim - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
filgrastim - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CSL-324 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CBLB-612 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PBI-4050 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
pegfilgrastim - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IBPB-004IG - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LG-7455 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ACN-8337 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
pegfilgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegfilgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
granulocyte colony-stimulating factor biobetter - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ST-7 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
pegfilgrastim - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Neutropenia - Recent Pipeline Updates 59
Neutropenia - Dormant Projects 63
Neutropenia - Discontinued Products 64
Neutropenia - Product Development Milestones 65
Featured News & Press Releases 65
Jul 24, 2014: FDA accepts Sandoz application for biosimilar filgrastim 65
Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 65
Feb 25, 2014: Teva UK Limited Launches Lonquex - A New Long-Acting G-CSF 66
Jan 23, 2014: Starpharma Commences Dendrimer-Docetaxel Clinical Trial 66
Dec 09, 2013: Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology 67
Nov 14, 2013: A*STAR Scientists Bring To Light Mechanism Of Drug For Infections 68
Oct 24, 2013: Starpharma's Dendrimer-Docetaxel eliminates neutropenia 69
Aug 08, 2013: European Commission grants marketing authorization for Teva's Lonquex 71
Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 71
Dec 12, 2012: Telik Announces Telintra Clinical Publication At 54th ASH Annual Meeting 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products under Development for Neutropenia, H2 2014 9
Number of Products under Development for Neutropenia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Neutropenia - Pipeline by Hospira, Inc., H2 2014 17
Neutropenia - Pipeline by Gamida Cell Ltd., H2 2014 18
Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 19
Neutropenia - Pipeline by Cleveland BioLabs, Inc., H2 2014 20
Neutropenia - Pipeline by CSL Limited, H2 2014 21
Neutropenia - Pipeline by ProMetic Life Sciences Inc., H2 2014 22
Neutropenia - Pipeline by Green Cross Corporation, H2 2014 23
Neutropenia - Pipeline by Genexine, Inc., H2 2014 24
Neutropenia - Pipeline by USV Limited, H2 2014 25
Neutropenia - Pipeline by Pfenex Inc., H2 2014 26
Neutropenia - Pipeline by Mycenax Biotech Inc., H2 2014 27
Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2014 28
Neutropenia - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Neutropenia Therapeutics - Recent Pipeline Updates, H2 2014 59
Neutropenia - Dormant Projects, H2 2014 63
Neutropenia - Discontinued Products, H2 2014 64